Arax Advisory Partners Has $30.94 Million Stock Position in Merck & Co., Inc. $MRK

Arax Advisory Partners lessened its position in shares of Merck & Co., Inc. (NYSE:MRK) by 31.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 293,929 shares of the company’s stock after selling 135,358 shares during the quarter. Merck & Co., Inc. makes up about 0.9% of Arax Advisory Partners’ investment portfolio, making the stock its 24th largest position. Arax Advisory Partners’ holdings in Merck & Co., Inc. were worth $30,939,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Merck & Co., Inc. by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock worth $26,770,014,000 after purchasing an additional 2,185,853 shares in the last quarter. State Street Corp grew its holdings in shares of Merck & Co., Inc. by 1.6% during the 4th quarter. State Street Corp now owns 120,040,168 shares of the company’s stock worth $12,737,504,000 after purchasing an additional 1,859,990 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Merck & Co., Inc. by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock worth $6,307,572,000 after purchasing an additional 249,110 shares in the last quarter. DLD Asset Management LP grew its holdings in shares of Merck & Co., Inc. by 30.1% during the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares in the last quarter. Finally, Morgan Stanley grew its holdings in shares of Merck & Co., Inc. by 0.8% during the 4th quarter. Morgan Stanley now owns 44,946,021 shares of the company’s stock worth $4,731,018,000 after purchasing an additional 359,486 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $119.05 on Friday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The company has a market capitalization of $294.04 billion, a PE ratio of 33.54, a price-to-earnings-growth ratio of 2.68 and a beta of 0.21. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $125.14. The business has a 50 day simple moving average of $116.55 and a 200 day simple moving average of $113.23.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.’s revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the company earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, sell-side analysts forecast that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MRK. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. UBS Group lifted their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. JPMorgan Chase & Co. lifted their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. Finally, Wells Fargo & Company decreased their price objective on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $128.18.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.